Clinical trials focus on new treatments for Crohn's Disease, dangerous bacterium

March 20, 2012 By Katie Pence

Several clinical trials at the University of Cincinnati (UC) are focused on potential treatments for two serious gastroenterological illnesses—Crohn’s disease and Clostridium difficile, or C. difficile.

Bruce Yacyshyn, MD, professor of medicine in the division of digestive diseases and principal investigator for the Cincinnati sites on both multicenter, international trials, says researchers are working with the pharmaceutical companies Janssen and Merck to find new therapies for a potentially life-altering autoimmune disease and for a condition, once only common in the autoimmune-compromised hospital population, that is now becoming an epidemic within the general population.

Yacyshyn says the first study—called UNITI-1—will examine how a Food and Drug Administration (FDA)-approved drug used for psoriasis may help in treating patients with Crohn’s disease who experience treatment failure with the other drugs commonly prescribed.

Crohn’s disease is an inflammatory bowel disease that occurs when the immune system attacks the gastrointestinal tract. Crohn’s can affect any part of the tract and inflame all layers of the intestinal wall; it most typically begins in younger years, with an average age of trouble occurring at 36.

Besides experiencing abdominal pain, bloody stools, diarrhea and other serious problems, such as growth failure because of a lack of nutrients, individuals with Crohn’s have an increased risk of colorectal cancer.

"There are currently three FDA-approved monoclonal biologic treatments for Crohn’s disease,” Yacyshyn says, explaining that these treatments are helpful because they target a pathway which activates the immune response in the body and produces the proteins that attack the gastrointestinal tract.”

"This clinical trial will focus on a therapy that will target a different pathway, giving hope to patients who have not experienced success with one of the other treatments or whose treatments begin to lose effect,” he adds.

The second clinical trial is looking at a single injection to see if this treatment could clear initial or recurrent onset of C. difficile.

C. difficile is a bacterium that can be naturally found inside the digestive tract, but if an overgrowth occurs, it can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Illness from C. difficile was once more common in older adults who were hospitalized or among people in long-term care facilities, and typically occurred after use of antibiotic medications.

"In recent years, C. diff infections have become more frequent, more severe and more difficult to treat,” says Yacyshyn, adding that treatment is expensive, ranging anywhere from $4,000 to $9,000. "Tens of thousands of people in the U.S. get sick from C. diff each year, and a rise in cases is being seen in the community—in healthy people who aren't hospitalized or taking antibiotics.”

In this Phase III trial, researchers will be giving individuals who currently test positive for C. difficile one of two antibodies which recognize the toxins produced by the bacteria.

"The infusion will be given with concurrent, standard-of-care antibiotic therapy. Following this one-time infusion, follow-up will occur over three months with a possible follow-up extension to nine months,” says Yacyshyn, adding that this is for patients 18 years or older. "There is currently no optimal treatment for all C. difficile-positive patients, and the antibiotics usually prescribed for it are not effective in all cases.  

"Addition of this treatment alongside current standard-of-care treatment may cut down on recurrence and help clear both toxin and bacteria after initial infection.

"While different, both of these conditions affect a large number of the population and could cause major complications if not treated properly,” he adds. "The hope is that these help in uncovering additional or more beneficial treatments for Crohn’s disease and C. difficile.”

Explore further: Single dose of antibiotic leaves mice highly vulnerable to intestinal infection

More information: Yacyshyn receives research support from Merck but cites no other conflict of interest.

Related Stories

Single dose of antibiotic leaves mice highly vulnerable to intestinal infection

January 20, 2012
Yet another study adds to the growing evidence that antibiotics can disrupt the balance of the intestinal flora, with negative effects on health. A team of researchers from the Memorial Sloan Kettering Cancer Center, New ...

Research identifies new way to treat common hospital-acquired infection

August 21, 2011
Researchers at the David Geffen School of Medicine at UCLA and the University of Texas Medical Branch at Galveston have discovered a molecular process by which the body can defend against the effects of Clostridium difficile ...

Recommended for you

Google searches can be used to track dengue in underdeveloped countries

July 20, 2017
An analytical tool that combines Google search data with government-provided clinical data can quickly and accurately track dengue fever in less-developed countries, according to new research published in PLOS Computational ...

MRSA emerged years before methicillin was even discovered

July 19, 2017
Methicillin resistant Staphylococcus aureus (MRSA) emerged long before the introduction of the antibiotic methicillin into clinical practice, according to a study published in the open access journal Genome Biology. It was ...

New test distinguishes Zika from similar viral infections

July 18, 2017
A new test is the best-to-date in differentiating Zika virus infections from infections caused by similar viruses. The antibody-based assay, developed by researchers at UC Berkeley and Humabs BioMed, a private biotechnology ...

'Superbugs' study reveals complex picture of E. coli bloodstream infections

July 18, 2017
The first large-scale genetic study of Escherichia coli (E. coli) cultured from patients with bloodstream infections in England showed that drug resistant 'superbugs' are not always out-competing other strains. Research by ...

Ebola virus can persist in monkeys that survived disease, even after symptoms disappear

July 17, 2017
Ebola virus infection can be detected in rhesus monkeys that survive the disease and no longer show symptoms, according to research published by Army scientists in today's online edition of the journal Nature Microbiology. ...

Mountain gorillas have herpes virus similar to that found in humans

July 13, 2017
Scientists from the University of California, Davis, have detected a herpes virus in wild mountain gorillas that is very similar to the Epstein-Barr virus in humans, according to a study published today in the journal Scientific ...


Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Mar 21, 2012
I believe the FDA has announced that PPI use can increase the chances of getting C diff. Since there are millions of people on PPI's, might that not be a contributing cause to C diff's increased cases?
not rated yet Mar 21, 2012
I am a Crohn's patient, when will this study start?
not rated yet Mar 21, 2012
Why is Crohn's becoming more common in the general population? Probably because food makers are increasingly putting unhealthy ingredients such as corn syrup in just about every product and it is hard for people to avoid. The billions the government spends on taxpayer subsidies for corn (to produce corn syrup) is one of the biggest scandals that so far is receiving little attention.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.